NeoGenomics, Inc. (NASDAQ:NEO – Free Report) – Investment analysts at Leerink Partnrs cut their Q1 2025 earnings estimates for shares of NeoGenomics in a research report issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of ($0.07) per share for the quarter, down from their prior forecast of ($0.02). The consensus estimate for NeoGenomics’ current full-year earnings is ($0.16) per share. Leerink Partnrs also issued estimates for NeoGenomics’ Q2 2025 earnings at ($0.03) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.10) EPS and FY2026 earnings at $0.07 EPS.
Other research analysts have also issued reports about the stock. Benchmark lowered shares of NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. Bank of America lifted their price target on NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of NeoGenomics in a research note on Friday, January 10th. Finally, Jefferies Financial Group initiated coverage on NeoGenomics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 target price for the company. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.30.
NeoGenomics Stock Up 1.1 %
NEO stock opened at $14.66 on Thursday. The company has a current ratio of 1.99, a quick ratio of 1.91 and a debt-to-equity ratio of 0.37. The firm has a 50 day simple moving average of $16.56 and a 200-day simple moving average of $15.68. The company has a market capitalization of $1.88 billion, a P/E ratio of -24.03 and a beta of 1.24. NeoGenomics has a twelve month low of $12.13 and a twelve month high of $19.11.
NeoGenomics (NASDAQ:NEO – Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The firm had revenue of $167.80 million during the quarter, compared to the consensus estimate of $167.00 million. During the same quarter in the prior year, the business posted ($0.06) earnings per share. NeoGenomics’s revenue for the quarter was up 10.5% on a year-over-year basis.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. Versant Capital Management Inc raised its stake in shares of NeoGenomics by 174.9% during the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 1,142 shares in the last quarter. Quarry LP acquired a new position in NeoGenomics during the 3rd quarter valued at about $40,000. Blue Trust Inc. raised its position in shares of NeoGenomics by 42.3% during the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after buying an additional 987 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of NeoGenomics in the 2nd quarter worth approximately $57,000. Finally, KBC Group NV boosted its holdings in shares of NeoGenomics by 33.1% in the third quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock valued at $67,000 after acquiring an additional 1,127 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.
Insider Activity at NeoGenomics
In related news, General Counsel Alicia C. Olivo sold 5,175 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $15.36, for a total value of $79,488.00. Following the sale, the general counsel now owns 37,129 shares of the company’s stock, valued at $570,301.44. This trade represents a 12.23 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.30% of the company’s stock.
About NeoGenomics
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Featured Stories
- Five stocks we like better than NeoGenomics
- What Do S&P 500 Stocks Tell Investors About the Market?
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- What is the Hang Seng index?
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.